XOMA Royalty (XOMA) Stock Price, News & Analysis

Company Overview

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

Key Stats

• Today's Range: $40.17 to $40.17
• 50-Day Range: $39.36 to $45.00
• 52-Week Range: $22.29 to $45.22
• Volume: N/A
• Average Volume: 497,905 shs
• Market Capitalization: $503.77 million
• P/E Ratio: 25.59
• Dividend Yield: N/A
• Price Target: $53.75
• Consensus Rating: Hold

XOMA Royalty Stock Analysis - MarketRank™

XOMA Royalty scored higher than 37% of companies evaluated by MarketBeat, and ranked 719th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

XOMA Royalty has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 1 buy rating, 6 hold ratings, and no sell ratings.

Upside Potential

XOMA Royalty has a consensus price target of $53.75, representing about 33.8% upside from its current price of $40.17.

Amount of Analyst Coverage

XOMA Royalty has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for XOMA Royalty are expected to decrease in the coming year, from $0.90 to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of XOMA Royalty is 25.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.15.

Price to Earnings Ratio vs. Sector

The P/E ratio of XOMA Royalty is 25.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.96.

Price to Book Value per Share Ratio

XOMA Royalty has a P/B Ratio of 5.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for XOMA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XOMA Royalty does not currently pay a dividend.

Dividend Growth

XOMA Royalty does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for XOMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XOMA Royalty insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.90% of the stock of XOMA Royalty is held by insiders.

Percentage Held by Institutions

95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 8/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XOMA
• CIK: 791908
• Web: www.xoma.com
• Phone: (510) 204-7200
• Fax: 510-649-7571
• Employees: 10
• Year Founded: 1981

Price Target and Rating

• Average Price Target for XOMA Royalty: $53.75
• High Price Target: $76.00
• Low Price Target: $39.00
• Potential Upside/Downside: +33.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.57
• Trailing P/E Ratio: 25.59
• Forward P/E Ratio: 44.63
• P/E Growth: N/A
• Net Income: $31.71 million
• Net Margins: 53.46%
• Pretax Margin: 69.85%
• Return on Equity: 12.56%
• Return on Assets: 4.11%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: $7.65 million
• Price / Sales: 65.83
• Cash Flow: $0.57 per share
• Price / Cash Flow: 70.46
• Book Value: $6.77 per share
• Price / Book: 5.93

Miscellaneous

• Outstanding Shares: 12,541,000
• Free Float: 11,425,000
• Market Cap: $503.77 million
• Optionable: Optionable
• Beta: 0.86